Temporary Abstract Submission lD:453152 Abstract Number for Publication:6510 Session Type and Title: Rapid Oral Abstract -Hematologic Malignancies-Leukemia, Mvelodysplastic Syndromes, and Allotransplant 在6月4日进行的宜明昂科2024 ASCO数据解读会上,可以详细了解到:IMM01联合阿扎胞苷治疗初治较高危的骨髓增生...
A $60 (USD) nonrefundable submission fee will be charged per abstract submitted. Payment is due at the time of submission. Credit cards are the only accepted form of payment. Checks, wire transfers, and purchase orders will not be accepted. Please note: The abstract submission fee does not ...
A $60 (USD) nonrefundable submission fee will be charged per abstract submitted. Payment is due at the time of submission. Credit cards are the only accepted form of payment. Checks, wire transfers, and purchase orders will not be accepted. Please note: The abstract submission fee does not ...
Late-Breaking Abstract Submission Deadline:October 19, 2023, at 12:00 PM (EST) Abstract Change/Withdrawal Deadline:December 7, 2023, at 12:00 PM (EST) Early November: Abstract Notifications Sent to First Authors 点此查看摘要指南>>>提交摘要>>> ASGO GI 2024 注册费: 线下:In-Person Registrat...
2024 ASCO Genitourinary Cancers Symposium(GU2024) Date: January 25-27, 2024 Venue: Moscone West, San Francisco, California, United States + Online 摘要征文投稿: Abstract Submission Deadline: September 26 at 11:59 PM (ET) 点此提交>>>查看更多摘要相关信息>>> ...
Temporary Abstract Submission ID:442762 Abstract Number for Publication: 5047 Session Type and Title: Poster Session – Genitourinary Cancer—Prostate, Testicular, and Penile Session Date and Time: 6/2/2024 9:00 AM-12:00 PM CDT 同宜医药创始人、董事长兼CEO黄保华博士表示: ...
6/3/2024 9:00 AM-12:00 PM CDT A Phase 1, Multi-Center, Open-Label, Dose-Escalation and Dose Expansion Study of CBP-1018, a Bi-Ligand-Drug Conjugate in Patients with Heavily Treated Advanced Solid Tumors Temporary Abstract Submission ID:442762Abstract Number for Publication: 5047Session Type...
[3]Garon EB, et al. TROPION-PanTumor01: Updated Results From the NSCLC Cohort of the Phase 1 Study of Datopotamab Deruxtecan in Solid Tumors. WCLC 2021. Abstract MA03.02. [4]Benjamin, L et al. TROPION-Lung02: Initial Results for Datopotamab Deruxtecan Plus Pembrolizumab and Platinu...
NOVEMBER 15, 2022 Abstract Submission Opens EARLY DECEMBER 2022 Member Registration and Hotel Reservations Opens MID-DECEMBER 2022 Registration and Hotel Reservations Opens to All FEBRUARY 14, 2023 Abstract Submission Deadline MARCH 16, 2023,Late-breaking Submission Deadline (Abstract placeholder is requir...
点击主页的 Submit Abstract 然后选择 Begin a Submission 选择论文的类型 填写论文名字 知情同意都同意 没有投过其他地方(投过的就不能在这里投了) 原创选 yes,综述总结类型选 no 临床试验选 yes 仔细选择文章额外信息 选择与文章最接近的主题 填写作者信息。只有 1 作才有点用 填写Conflict of Interest,点每个...